These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33764520)

  • 1. LmjF.36.3850, a novel hypothetical Leishmania major protein, contributes to the infection.
    Zutshi S; Sarode AY; Ghosh SK; Jha MK; Sudan R; Kumar S; Sadhale LP; Roy S; Saha B
    Immunology; 2021 Aug; 163(4):460-477. PubMed ID: 33764520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania major adenylate kinase immunization offers partial protection to a susceptible host.
    Zutshi S; Kumar S; Sarode A; Roy S; Sarkar A; Saha B
    Parasite Immunol; 2020 Feb; 42(2):e12688. PubMed ID: 31797390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
    Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
    J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection.
    Roberts MT; Stober CB; McKenzie AN; Blackwell JM
    Infect Immun; 2005 Nov; 73(11):7620-8. PubMed ID: 16239566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
    Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
    Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses.
    Arendse B; Van Snick J; Brombacher F
    J Immunol; 2005 Feb; 174(4):2205-11. PubMed ID: 15699153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Characterization of an Avirulent
    Jha MK; Sarode AY; Bodhale N; Mukherjee D; Pandey SP; Srivastava N; Rub A; Silvestre R; Sarkar A; Saha B
    J Immunol; 2020 May; 204(10):2734-2753. PubMed ID: 32245818
    [No Abstract]   [Full Text] [Related]  

  • 14. KM(+), a lectin from Artocarpus integrifolia, induces IL-12 p40 production by macrophages and switches from type 2 to type 1 cell-mediated immunity against Leishmania major antigens, resulting in BALB/c mice resistance to infection.
    Panunto-Castelo A; Souza MA; Roque-Barreira MC; Silva JS
    Glycobiology; 2001 Dec; 11(12):1035-42. PubMed ID: 11805076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitigating an undesirable immune response of inherent susceptibility to cutaneous leishmaniosis in a mouse model: the role of the pathoantigenic HISA70 DNA vaccine.
    Domínguez-Bernal G; Horcajo P; Orden JA; De La Fuente R; Herrero-Gil A; Ordóñez-Gutiérrez L; Carrión J
    Vet Res; 2012 Aug; 43(1):59. PubMed ID: 22876751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S; Singh S; Saha B; Paliwal PK
    Vaccine; 2011 Nov; 29(48):8783-7. PubMed ID: 21527301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response.
    Alexander J; Coombs GH; Mottram JC
    J Immunol; 1998 Dec; 161(12):6794-801. PubMed ID: 9862710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
    Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
    Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.